Because fractional intestinal absorption remains unchanged at ∼60% in CKD, a usual intake of phosphorus in these patients will lead to phosphorus retention in the body with the subsequent increased risk of vascular calcifications, higher levels of PTH (less bone mass), and higher levels of FGF-23 (a cardiac toxin). This evidence concerns the gene FGF23 and chronic kidney disease.